Peptide Benefits: What the Research Shows

Peptides are short chains of amino acids that act as signalling molecules in biological pathways, and their benefits depend entirely on which specific compound, receptor and evidence base you examine. Human clinical trials published through 2026 show that GLP-1 receptor agonists and multi-agonist compounds deliver measurable weight-loss outcomes, with tirzepatide 15 mg achieving a mean −17.97% body-weight reduction and CagriSema reaching −17.84% in network meta-analysis of randomised trials [2]. For other widely marketed peptides, including BPC-157, TB-500, GHK-Cu and MOTS-c, the benefits rest mainly on animal studies, mechanistic rationale or small pilot data rather than proven human results [5][6][7].

This guide separates the evidence that exists from the claims that do not, and shows how to check a peptide product before you commit.

What you will learn:

• Which peptide categories have proven human evidence versus marketing claims
• How to tell proven human evidence from marketing claims
• A practical method to evaluate peptide claims before purchasing

What are peptides?

A peptide is a short chain of amino acids, typically fewer than 50, that acts as a signalling molecule in biological pathways, distinct from larger proteins by both size and function [6]. Peptides are not a single treatment or supplement category; the term describes a broad molecular class that includes prescription therapies like semaglutide, investigational compounds such as retatrutide, cosmetic peptides used in skincare, and research-use products sold without human approval.

Martínez-Villaluenga et al. reviewed the mechanism that makes peptides interesting, tissue penetration and high-affinity receptor binding, in 2022, noting these properties do not automatically translate into proven clinical outcomes. A peptide's effect depends entirely on its specific amino acid sequence, the receptor it targets, and whether human trials have validated the proposed benefit. Evidence for GLP-1 weight-management compounds cannot be applied to recovery or wellness peptides sold for different purposes.

Which peptide benefits have the strongest evidence?

Peptide benefits are not uniform across the category; the strongest human evidence exists for GLP-1 and multi-agonist weight management compounds, while recovery, cosmetic and wellness claims rest on weaker foundations [2][6]. The hierarchy runs from large randomised trials (semaglutide, tirzepatide, CagriSema) through smaller human studies, animal models, laboratory mechanisms, and finally to anecdotal or marketing claims with no independent verification [2][5].

GLP-1 receptor agonists and dual/triple agonists occupy the top tier. A 2026 network meta-analysis of 25 randomised trials found tirzepatide 15 mg produced mean weight reduction of -17.97%, CagriSema -17.84%, and semaglutide 7.2 mg -14.66% in adults with overweight or obesity, with cardiometabolic secondary endpoints including glycated haemoglobin (HbA1c), waist circumference and body mass index (BMI) [2]. The Phase 3 REIMAGINE 5 trial (NCT06534411) for CagriSema in type 2 diabetes, reported in 2026, used relative body-weight change and HbA1c as primary outcomes at 60 weeks in 1,023 participants [1]. These are compound-specific results; they do not transfer to other peptide classes.

Recovery and tissue-repair peptides such as BPC-157 and TB-500 sit lower in the evidence hierarchy. A 2026 orthopaedic primer noted mechanistic rationale for soft-tissue and tendon repair, but described human evidence as largely unvalidated [5]. The same year, a gerontology review classified these compounds as not approved and supported mainly by preclinical or pilot data [6].

Cosmetic and wellness peptides, including GHK-Cu, MOTS-c, nicotinamide adenine dinucleotide (NAD+), melanotan II and glutathione, lack robust human trial evidence in the 2024-2026 literature for consumer-marketed indications [7][8]. A 2026 critical appraisal found no reviewed compound in this group had established clinical efficacy in adequately powered randomised controlled trials [8].

This article uses a five-level framework to classify evidence: human randomised trials, human observational studies, animal or laboratory research, mechanistic rationale only, and unsubstantiated marketing language. The matrix in the next section applies this framework to each claimed benefit. Readers considering how peptide injections are administered should consult the dedicated procedural guide; those interested in antioxidant claims can explore BeSkinny's glutathione range.

Weight management: where human evidence is strongest

GLP-1 and multi-agonist compounds have the strongest human evidence among peptide-related categories, with randomised trials showing measurable weight loss in adults with overweight or obesity [2]. This evidence base separates them from research-use peptides that rely mainly on animal or laboratory data.

The 2026 network meta-analysis of 25 randomised trials found tirzepatide 15 mg produced the greatest mean percent weight reduction at -17.97%, followed by CagriSema at -17.84% and semaglutide 7.2 mg at -14.66%. These figures represent adults with overweight or obesity, with outcomes including percent body weight, waist circumference, BMI, and thresholds from ≥5% to ≥20% weight loss. CagriSema showed the highest proportion of participants reaching ≥20% weight loss, though gastrointestinal adverse events increased with treatment intensity.

Retatrutide remains investigational; no primary randomised human weight-loss trial record was retrievable in the 2026 sources consulted, so its status should be treated as unverified. CagriSema has Phase 3 data: the REIMAGINE 5 trial (NCT06534411) enrolled 1,023 adults with type 2 diabetes on metformin or sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy, with primary endpoints of HbA1c change and relative body-weight change at 60 weeks [1].

Gastrointestinal adverse events are the most consistently reported side effect across GLP-1 and multi-agonist trials, with discontinuation highest for semaglutide 7.2 mg in the 2026 meta-analysis.

Learn how BeSkinny handles testing and fulfilment or explore the semaglutide guide for South African buyers.

Recovery, repair and muscle claims

Recovery and repair claims for peptides rest mainly on animal-model and laboratory evidence rather than proven human clinical outcomes. BPC-157 and TB-500, the two compounds most commonly associated with tissue repair, have shown promising mechanistic findings in preclinical studies but remain largely unvalidated in human trials as of 2026 [2][5][6].

BPC-157 and TB-500: the evidence gap

BPC-157 is a synthetic pentadecapeptide derived from a protective protein in human gastric juice. In animal studies, it has demonstrated effects on tendon, ligament and muscle healing through angiogenic and anti-inflammatory pathways [6]. A 2026 orthopaedic and sports medicine primer notes these potential tendon and muscle-repair effects but states explicitly that they are "largely unvalidated in human trials," citing only a small human case series with major methodological limitations [2].

TB-500, a synthetic version of thymosin beta-4, shows similar preclinical patterns. The 2026 PMC review on therapeutic peptides in gerontology places TB-500 mainly in the animal-study category, noting Phase I safety evidence in humans but no established clinical efficacy for recovery outcomes [6]. No adequately powered randomised controlled trial retrieved in 2024-2026 demonstrates proven human recovery benefit for either compound [5][6].

Muscle growth and growth-hormone-related research

CJC-1295 and ipamorelin are frequently grouped with recovery claims due to their growth-hormone-releasing properties. These compounds stimulate pituitary growth hormone secretion through distinct mechanisms: CJC-1295 as a growth hormone-releasing hormone (GHRH) analogue with extended half-life, ipamorelin as a selective ghrelin receptor agonist. However, the 2026 literature review found no human clinical trial establishing that this combination produces measurable muscle growth or strength gains superior to placebo in trained individuals [7]. Claims of proven muscle-building effects remain unsupported by the current evidence base.

What "mechanism" does and does not mean

A compound showing tissue-repair mechanisms in cell culture or rodent models does not establish that it repairs human injuries. Mechanistic evidence explains how a biological pathway might operate; clinical evidence establishes whether it produces meaningful outcomes in patients. The 2026 PMC review distinguishes these levels explicitly, categorising BPC-157, TB-500 and related compounds as "not approved" and supported mainly by preclinical or pilot data [6].

For South African buyers, this distinction matters because wellness and recovery peptides are available as research compounds, but their documented benefits do not include proven human recovery. Those considering how peptide injections are administered should understand that administration method does not overcome the underlying evidence gap for these specific claims.

Skin, energy and other proposed benefits

Cosmetic, metabolic and wellness peptide claims draw heavily on biochemical rationale, but human clinical evidence for these specific compounds remains limited or absent in the 2024-2026 literature.

GHK-Cu for skin health

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is promoted for skin elasticity, hydration and anti-ageing effects. A 2022 review outlined mechanisms including collagen synthesis stimulation and antioxidant activity, yet the 2026 PMC review on unregulated peptide use lists GHK-Cu among compounds with no established clinical efficacy in adequately powered human trials [6][7]. Mechanistic plausibility does not equate to proven cosmetic outcomes. The 2026 critical appraisal of peptide evidence similarly found no reviewed compound in this category had demonstrated efficacy for consumer-marketed indications [8].

MOTS-c and NAD+ for cellular energy

MOTS-c (mitochondrial-derived peptide) and NAD+ are positioned for metabolic health and cellular energy. The 2026 PMC review describes MOTS-c as a regulator of metabolic homeostasis with promising preclinical findings, but human randomised trial data for marketed products was not identified [6]. NAD+ precursors have extensive mechanistic literature regarding sirtuin activation and mitochondrial function; however, the same 2026 appraisal notes that NAD+ and related compounds lack established clinical efficacy for the wellness claims commonly advertised [8]. Those interested in NAD+ products should understand that available research does not currently support specific outcome predictions.

Melanotan II and glutathione

Melanotan II, a synthetic melanocortin analogue, is marketed for tanning and appetite suppression. The 2026 PMC review classifies it among peptides used in biohacking settings without approved indications or robust human safety data [6].

Glutathione is promoted for antioxidant and "detoxification" benefits. While glutathione is an endogenous antioxidant with established biochemical roles, the 2026 literature review did not identify human clinical trials demonstrating that exogenous glutathione peptide supplementation produces the wellness outcomes claimed in consumer marketing [7][8]. Those exploring BeSkinny's glutathione range should note that biochemical rationale and clinical proof are distinct evidence categories.

The pattern across wellness peptides

The 2024-2026 evidence base shows a consistent pattern: mechanistic studies and animal models generate hypotheses that are then marketed as established benefits before human trials validate them. The 2026 orthopaedic primer explicitly warns that "apparent benefits in preclinical models do not translate to proven human outcomes" [5]. For skin, energy and wellness claims specifically, the gap between proposed mechanism and clinical evidence remains substantial.

Peptide benefits and side effects

There is no single side-effect profile for peptides. Adverse effects depend on the specific compound, dose, route, formulation quality and the user's underlying health conditions. The strongest human evidence exists for GLP-1 and multi-agonist compounds, where gastrointestinal symptoms dominate; for research-stage peptides, safety data remain largely theoretical or animal-derived.

GLP-1 and multi-agonist compounds: established adverse events

Human trials and regulator documents from 2024-2026 consistently report gastrointestinal adverse events as the primary side-effect category for semaglutide, tirzepatide and related compounds. A 2026 network meta-analysis found that GI adverse events increased across all treatments in the advanced anti-obesity class, with treatment discontinuation highest at semaglutide 7.2 mg [2]. Serious adverse events were comparable to placebo in the same analysis [2].

Standard trial exclusions for these compounds include pregnancy or breastfeeding, estimated glomerular filtration rate below 30 mL/min/1.73 m², and unstable diabetic retinopathy or maculopathy [1]. Specific contraindications and boxed warnings on registered product labels should be verified with current prescribing information.

Research-stage and unregistered peptides: uncertainty dominates

For BPC-157, TB-500, GHK-Cu, MOTS-c, melanotan II and similar compounds, human safety data are sparse. A 2026 orthopaedic primer notes that BPC-157 findings remain largely unvalidated in human trials, with only small case series and methodological limitations [5]. The 2026 PMC review on unregulated peptide use classifies TB-500 as supported mainly by animal studies, with only Phase I safety rather than efficacy evidence in humans [6]. Melanotan II carries specific pigmentation-related concerns [6].

Route and formulation risks

Injectable delivery introduces risks absent from oral routes: injection-site reactions, sterile abscess formation, and, critically for unregulated products, uncertainty about sterility, pyrogen content and actual peptide identity. Unregulated injectable products may lack analytical testing for identity and potency.

When to seek medical help

Seek immediate medical attention for signs of severe allergic reaction, persistent vomiting with dehydration, or symptoms of pancreatitis (severe abdominal pain radiating to the back). Any adverse event should be reported to a healthcare provider.

Personal medical advice requires consultation with a qualified South African prescriber. The information here documents published evidence, not individual risk assessment.

Those wanting to understand our quality-control documentation and fulfilment standards can read how BeSkinny handles testing and fulfilment.

How to judge a peptide claim before buying

A reliable claim-check separates the compound from the marketing: name the exact molecule, match the evidence type to the promised benefit, and verify what documentation actually proves. A Certificate of Analysis (CoA) documents batch-level purity and identity testing; it does not establish clinical efficacy, sterility, or that a product is safe for your specific use.

A repeatable claim-checking method

Use this sequence before any purchase:

1. Identify the exact compound. "Peptide" is a category, not a product. Semaglutide, tirzepatide, BPC-157, and TB-500 have different evidence profiles and cannot be substituted for one another.
2. Locate human evidence for your specific goal. GLP-1 and multi-agonist compounds have randomised trial data for weight management from 2026 [2]. Recovery, skin, and wellness claims for other peptides rest mainly on animal or laboratory studies [5][6][7].
3. Check dose, route, and formulation match. A study using 2.4 mg semaglutide subcutaneously does not validate a different strength, oral preparation, or compounded variant.
4. Request batch documentation. We state that every batch is third-party tested for purity and identity, with a CoA available on the relevant product page or by email request. This documents our quality-control process, not independent proof of efficacy or medical safety.
5. Confirm cold-chain handling. Peptide stability depends on temperature. We handle products cold-chain from storage through dispatch; weight-loss pens ship with a gel pack to maintain integrity during transport.
6. Reject guaranteed-result language. No peptide produces identical outcomes across individuals. Claims of assured weight loss, muscle gain, or recovery speed indicate marketing over evidence.

What a CoA cannot establish

A CoA typically covers identity, purity, and concentration for the specific batch tested. It does not demonstrate:

• Sterility or pyrogen-free status (unless explicitly included)
• Clinical efficacy in humans
• Safety for your medical history or concurrent medications

Readers who want compound-specific weight-management evidence and product details can continue to the semaglutide guide for South African buyers. Those comparing recovery and wellness compounds after reading the evidence matrix can view wellness and recovery peptides.

Peptide benefits: questions readers still ask

Do all peptides work the same way?

No. Peptides are short chains of amino acids that act as signalling molecules, but their effects depend entirely on the specific sequence, target receptor and biological pathway involved [2][6]. Evidence for one peptide cannot be generalised to the entire category.

Which peptide category has the strongest human evidence?

GLP-1 and multi-agonist compounds for weight management have the strongest human evidence in 2026. A network meta-analysis of randomised trials found tirzepatide 15 mg achieved mean weight reduction of -17.97%, CagriSema -17.84% and semaglutide 7.2 mg -14.66% [2].

Is BPC-157 proven for human recovery?

No. BPC-157 shows tendon and muscle-repair effects in animal models, but a 2026 orthopaedic primer states these findings remain largely unvalidated in human trials [2][5]. Only a small human case series with methodological limitations has been reported.

Does a Certificate of Analysis prove safety or efficacy?

A CoA documents third-party testing for purity and identity for a specific batch. It does not prove clinical efficacy, sterility assurance or medical safety for individual use. We state every batch is third-party tested with CoA availability; this reflects our quality-control process, not independent evidence of outcomes.

Should you choose a peptide without a prescriber?

This article does not provide medical advice. Consult a registered healthcare practitioner for individual guidance.

Shop the full peptide range, every compound, in the strengths that matter.

Sources

• [1] Study Details | NCT06534411 | ClinicalTrials.gov - ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT06534411, 2026
• [2] Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials, https://pubmed.ncbi.nlm.nih.gov/42207966/, 2026
• [3] SAHPRA and the SAPC Crack Down on Unlawful Manufacturing of Unregistered GLP-1 Medicines, https://www.sahpra.org.za/sahpra-and-the-sapc-crack-down-on-unlawful-manufacturing-of-unregistered-glp-1-medicines/, 2026
• [4] Health regulators warn against the use or dispensing of recalled Semaglutide and Tirzepatide, https://www.sahpra.org.za/health-regulators-warn-against-the-use-or-dispensing-of-recalled-semaglutide-and-tirzepatide/, 2026
• [5] Injectable Peptide Therapy: A Primer for Orthopaedic and Sports ..., https://pubmed.ncbi.nlm.nih.gov/41476424/, 2026
• [6] Therapeutic peptides in gerontology: mechanisms and ... - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC13095733/, 2026
• [7] Unregulated Peptide Use in the Age of Biohacking - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC13355462/, 2026
• [8] The peptide boom: a critical appraisal of evidence, patient ..., https://gmj.ge/index.php/pub/article/download/200/142, 2026